Laryngeal mask airway insertion response Hypertension Tachycardia
Conditions
Interventions
Sufentanil Group:Induction with sufentanil
Tegileridine Group T1:Induction with tegileridine at 20 µg/kg
Tegileridine Group T2:Induction with tegileridine at 30 µg/kg
Tegileridine Group T3:Induction with tegileridine at 40 µg/kg
Sponsors
The First People’s Hospital of Lianyungang
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age > 65 years old; 2.ASA I~III; 3.BMI 18.5~27.9 kg/m^2; 4.Mallampati class I or II, with mouth opening >2.5 cm; 5.All participants voluntarily joined this study and signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Contraindications for laryngeal mask airway use including: full stomach, oropharyngeal structural abnormalities, gastroesophageal reflux disease , etc; 2.Alcohol or drug abuse and allergy to any medication used in the study; 3.patients with severe dysfunction of major organ systems (cardiac, pulmonary, hepatic, renal, or neurological); 4.History of long-term psychotropic medication use or cognitive dysfunction;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laryngeal mask airway insertion response; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of moderate to severe nausea and vomiting within 24 hours after surgery was recorded;Hypotension after induction; | — |
Countries
China
Contacts
Public ContactXiaobao Zhang;Guangrong Dai
The First People’s Hospital of Lianyungang
Outcome results
None listed